Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Alzheimer's Disease Market Will Surpass $10 Billion by 2021, Says GBI Research | ||
| By: PR Newswire Association LLC. - 10 Feb 2016 | Back to overview list |
|
LONDON, February 10, 2016 /PRNewswire/ -- A new report from business intelligence provider GBI Research - Alzheimer's Disease Therapeutics Market to 2021 - states that the Alzheimer's disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion in 2021, at a Compound Annual Growth Rate (CAGR) of 11%. This impressive market growth will occur across the eight major markets (8MM) of the US, Canada, France, Germany, Italy, Spain, the UK, and Japan, and will primarily be driven by increased disease prevalence during the forecast period. Senior Analyst Yasser Mushtaq says: "Alzheimer's disease is significantly more common in the older population and incidence rates increase rapidly after the age of 65. The fact that people are living longer across the globe means more cases of the disease are developing, and this has posed a growing public health crisis, which represents a very serious disease burden for patients and carers alike.Despite the urgent need to develop more effective treatments for Alzheimer's disease, thorough research is being carried out into understanding the disease, as its underlying pathology remains unknown. However, these extensive studies have helped to develop the research and development process within this indication, providing hope for the future of Alzheimer's disease therapeutics." GBI Research also states that although disease prevalence will be the strongest driver of market growth, innovation in the pipeline will also be a factor. Mushtaq explains: "While many of the later-stage therapies focus on common targets, the earlier stages of the pipeline do not appear to follow this trend, as they contain many first-in-class molecules with novel molecular targets within the context of Alzheimer's disease therapeutics. The primary new approvals for drugs that will drive growth during the forecast period will supplement current market leaders and offer greater therapeutic options. Promising examples include verubecestat, aducanumab and azeliragon, all of which have demonstrated clinical benefit and will be approved during the forecast period." Sample pages of GBI Research's report Alzheimer's Disease Therapeutics Market to 2021 are available upon request About GBI Research GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends. Connect with GBI Research on social media for the latest healthcare market updates:
SOURCE GBI Research 
|
||
|
|
||
 | Back to overview list | |